Jefferies Keeps Lowest Rating on Arena Pharma (ARNA) After Q4 Call and Into May Lorcaserin Panel

Go back to Jefferies Keeps Lowest Rating on Arena Pharma (ARNA) After Q4 Call and Into May Lorcaserin Panel